Page last updated: 2024-09-05

sorafenib and cysteine

sorafenib has been researched along with cysteine in 8 studies

Compound Research Comparison

Studies
(sorafenib)
Trials
(sorafenib)
Recent Studies (post-2010)
(sorafenib)
Studies
(cysteine)
Trials
(cysteine)
Recent Studies (post-2010) (cysteine)
6,5207305,25131011
6,5207305,25140,13241811,457

Protein Interaction Comparison

ProteinTaxonomysorafenib (IC50)cysteine (IC50)
Excitatory amino acid transporter 1Homo sapiens (human)376
Excitatory amino acid transporter 3Homo sapiens (human)161

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (37.50)24.3611
2020's5 (62.50)2.80

Authors

AuthorsStudies
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Álamo-Martínez, JM; Barcena, JA; Barrera-Pulido, L; Bernal-Bellido, C; Blanco-Fernández, G; Gila-Bohórquez, A; Gómez-Bravo, MA; González, R; Marín-Gómez, LM; Muntané, J; Navarro-Villarán, E; Nogales-Muñoz, A; Pacheco, D; Padilla, CA; Padillo, FJ; Pereira, S; Rodríguez-Hernández, A; Sarrias-Giménez, A; Serrablo-Requejo, A; Serrano-Díaz-Canedo, J; Soriano-De Castro, LB; Suárez-Artacho, G; Torres-Nieto, MA1
Barbare, JC; Barget, N; Bodeau, S; Chauffert, B; Coriat, R; François, C; Galmiche, A; Ganne, N; Godin, C; Gutierrez, L; Houessinon, A; Louandre, C; Mongelard, G; Régimbeau, JM; Saidak, Z; Sauzay, C; Takahashi, S1
Capelletti, MM; Manceau, H; Peoc'h, K; Puy, H1
Deterding, LJ; Gao, X; Ji, M; Kang, K; Li, L; Li, X; Li, Y; Liu, J; Locasale, JW; Shats, I; Tong, L; Tong, X; Williams, JG; Xu, Q1
Du, J; Li, Y; Ren, X; Shao, F; Wu, H; Xia, J; Yu, J; Zhou, Y1
Byun, JK; Choi, YK; Kang, GW; Lee, J; Lee, S; Lee, YR; Park, KG; Park, SY; Song, IS; Yun, JW1
Guo, F; Jin, X; Meng, J; Ren, D; Sun, Y; Wu, H; Zhang, H1

Reviews

2 review(s) available for sorafenib and cysteine

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
Ferroptosis in Liver Diseases: An Overview.
    International journal of molecular sciences, 2020, Jul-11, Volume: 21, Issue:14

    Topics: alpha-Tocopherol; Animals; Autophagy; Chemical and Drug Induced Liver Injury; Cyclohexylamines; Cysteine; Ferroptosis; Glutathione; Heme; Humans; Iron; Kelch-Like ECH-Associated Protein 1; Lipid Peroxidation; Lipoxygenase; Liver Diseases; Liver Neoplasms; Oxidative Stress; Phenylenediamines; Phospholipid Hydroperoxide Glutathione Peroxidase; Piperazines; Quinoxalines; Reactive Oxygen Species; Reperfusion Injury; Signal Transduction; Sorafenib; Spiro Compounds; Sulfasalazine; Tumor Suppressor Protein p53

2020

Other Studies

6 other study(ies) available for sorafenib and cysteine

ArticleYear
Regulation of cell death receptor S-nitrosylation and apoptotic signaling by Sorafenib in hepatoblastoma cells.
    Redox biology, 2015, Volume: 6

    Topics: Antineoplastic Agents; Caspase 3; Caspase 8; Caspase 9; Cell Death; Cysteine; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Niacinamide; Nitric Oxide; Nitric Oxide Donors; Nitric Oxide Synthase Type III; Phenylurea Compounds; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor, Type I; S-Nitrosothiols; Signal Transduction; Sorafenib

2015
Metallothionein-1 as a biomarker of altered redox metabolism in hepatocellular carcinoma cells exposed to sorafenib.
    Molecular cancer, 2016, 05-16, Volume: 15, Issue:1

    Topics: Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Cell Line, Tumor; Cysteine; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Metallothionein; NF-E2-Related Factor 2; Niacinamide; Oxidation-Reduction; Oxidative Stress; Phenylurea Compounds; Prognosis; Promoter Regions, Genetic; Protein Kinase Inhibitors; Sorafenib; Transcription, Genetic

2016
HNF4α regulates sulfur amino acid metabolism and confers sensitivity to methionine restriction in liver cancer.
    Nature communications, 2020, 08-07, Volume: 11, Issue:1

    Topics: Animals; Biomarkers, Tumor; Cell Line, Tumor; Cell Movement; Cysteine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Neoplastic; Hepatocyte Nuclear Factor 4; Liver; Liver Neoplasms; Mesoderm; Metabolic Networks and Pathways; Metabolome; Methionine; Mice; Sorafenib; Transcription, Genetic

2020
Sorafenib induces mitochondrial dysfunction and exhibits synergistic effect with cysteine depletion by promoting HCC cells ferroptosis.
    Biochemical and biophysical research communications, 2021, 01-01, Volume: 534

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cysteine; Ferroptosis; Glutathione; Humans; Liver Neoplasms; Mitochondria; Reactive Oxygen Species; Sorafenib

2021
Macropinocytosis is an alternative pathway of cysteine acquisition and mitigates sorafenib-induced ferroptosis in hepatocellular carcinoma.
    Journal of experimental & clinical cancer research : CR, 2022, Mar-14, Volume: 41, Issue:1

    Topics: Animals; Carcinoma, Hepatocellular; Cysteine; Female; Ferroptosis; Humans; Liver Neoplasms; Male; Mice; Pinocytosis; Protein Kinase Inhibitors; Sorafenib

2022
S-palmitoylation of PCSK9 induces sorafenib resistance in liver cancer by activating the PI3K/AKT pathway.
    Cell reports, 2022, 08-16, Volume: 40, Issue:7

    Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cysteine; Drug Resistance, Neoplasm; Hep G2 Cells; Humans; Lipoylation; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Proprotein Convertase 9; Proto-Oncogene Proteins c-akt; Sorafenib

2022